What it's for (Indications)
- Levosulpiride, an enantiomer of sulpiride, is primarily utilized for its prokinetic, antiemetic, and anxiolytic properties derived from its selective dopamine D2 receptor antagonism.
- Its indications vary geographically but commonly include the treatment of functional dyspepsia, characterized by symptoms such as epigastric pain, bloating, early satiety, and nausea, particularly when associated with delayed gastric emptying.
- It is also used in the management of irritable bowel syndrome (IBS) predominantly with constipation, due to its ability to enhance gastrointestinal motility.
- Furthermore, levosulpiride may be prescribed for symptomatic relief of vertigo, nausea, and vomiting of various etiologies, including Ménière's disease or post-surgical emesis.
- In some regions, it is also indicated for adjunctive therapy in mood and anxiety disorders, leveraging its central dopaminergic effects, though this use requires careful consideration given its side effect profile.
- Its prokinetic action is particularly beneficial in conditions where impaired gastric motility contributes to symptoms, aiming to restore physiological gut function and alleviate discomfort.
- The therapeutic application of levosulpiride should always be carefully weighed against its potential risks and contraindications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of levosulpiride must be individualized based on the patient's condition, severity of symptoms, and response to treatment, with careful consideration of its safety profile. For adults, the typical oral dosage for conditions such as functional dyspepsia or irritable bowel syndrome usually ranges from 25 mg to 75 mg per day, administered in divided doses (e.g., 25 mg two to three times daily) before meals. In specific cases requiring more intensive symptomatic control, a higher dosage might be considered, but always under strict medical supervision and for the shortest possible duration. For the treatment of vertigo, nausea, and vomiting, similar dosages are generally applied. Renal impairment necessitates dosage adjustment, as levosulpiride is primarily excreted by the kidneys; a reduced dose is recommended in patients with moderate to severe renal dysfunction to prevent accumulation and potential toxicity. Elderly patients may also require a lower starting dose and careful titration due to increased sensitivity to adverse effects and potential age-related decline in renal function. Intramuscular or intravenous formulations may be available for acute situations requiring rapid relief, with dosages typically ranging from 25 mg to 50 mg given once or twice daily, not exceeding 7 days, before transitioning to oral therapy. Adherence to prescribed dosages and duration of treatment is crucial to optimize efficacy and minimize risks. |
Safety & Warnings
Common Side Effects
- Levosulpiride, as a dopamine D2 receptor antagonist, is associated with a range of side effects, many of which are dose-dependent and related to its pharmacological action.
- The most common adverse effects involve the endocrine system due to its impact on prolactin secretion.
- Hyperprolactinemia can manifest as galactorrhea (abnormal milk production), amenorrhea (absence of menstruation), menstrual irregularities, gynecomastia (breast enlargement in males), and sexual dysfunction (e.
- g.
- , decreased libido, erectile dysfunction).
- Neurological side effects are also frequent and can include sedation, drowsiness, insomnia, headache, and dizziness.
- Extrapyramidal symptoms (EPS) such as tremor, akathisia (restlessness), dystonia (involuntary muscle contractions), and tardive dyskinesia (involuntary repetitive movements, particularly of the face and tongue) are serious but less common adverse events that can occur, especially with prolonged use or higher doses.
- Gastrointestinal disturbances like constipation or diarrhea, and dry mouth are also reported.
- Cardiovascular effects, though rare, can include QT interval prolongation, which increases the risk of serious ventricular arrhythmias (e.
- g.
- , Torsades de Pointes).
- Allergic reactions, including rash and urticaria, are possible.
- Patients should be closely monitored for any emergence of these side effects, and prompt medical attention should be sought if serious adverse events occur.
Serious Warnings
- Black Box Warning: ### Serious Warnings: Neuroleptic Malignant Syndrome, Extrapyramidal Symptoms, and QT Prolongation While levosulpiride is not approved by the U.S. Food and Drug Administration (FDA) and therefore does not carry an FDA-issued Black Box Warning, clinicians and patients must be aware of several severe, potentially life-threatening risks associated with its use, similar to other dopamine receptor antagonists. These serious warnings are critical for patient safety and reflect the drug's pharmacological profile. **Neuroleptic Malignant Syndrome (NMS):** Levosulpiride can induce Neuroleptic Malignant Syndrome, a rare but potentially fatal idiosyncratic reaction characterized by high fever, muscle rigidity, altered mental status, and autonomic instability (e.g., irregular pulse or blood pressure, tachycardia, diaphoresis, cardiac arrhythmias). Prompt recognition and immediate discontinuation of levosulpiride, along with intensive symptomatic treatment, are crucial. Given the severity of NMS, patients and caregivers should be educated on its signs and symptoms, and medical attention should be sought immediately if they appear. **Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia:** As a dopamine D2 receptor antagonist, levosulpiride carries a significant risk of inducing dose-dependent and duration-dependent extrapyramidal symptoms, including acute dystonia, akathisia, and parkinsonism. Of particular concern is the potential for tardive dyskinesia (TD), a syndrome of potentially irreversible, involuntary, dyskinetic movements, especially of the face and tongue. The risk of TD increases with treatment duration and cumulative dose, and it can occur even after discontinuation of the drug. Patients, especially the elderly, should be monitored closely for the emergence of EPS or TD, and the drug should be discontinued if these symptoms develop. **QT Interval Prolongation and Cardiac Arrhythmias:** Levosulpiride has been associated with dose-dependent prolongation of the QT interval on the electrocardiogram, which can lead to life-threatening ventricular arrhythmias, including Torsades de Pointes. This risk is increased in patients with pre-existing cardiac conditions (e.g., heart failure, bradycardia, myocardial infarction), electrolyte disturbances (hypokalemia, hypomagnesemia), or concomitant use of other drugs known to prolong the QT interval. Extreme caution is advised, and baseline and periodic ECG monitoring, along with electrolyte checks, should be considered, especially in high-risk patients. If signs of arrhythmia or significant QT prolongation occur, levosulpiride should be immediately discontinued. **Hyperprolactinemia:** Levosulpiride can cause significant and persistent elevation of serum prolactin levels, which may lead to endocrine disturbances such as amenorrhea, galactorrhea, gynecomastia, and sexual dysfunction. Chronic hyperprolactinemia can be associated with bone demineralization and an increased risk of osteopenia/osteoporosis. This effect warrants monitoring, particularly in patients on long-term therapy or those with pre-existing prolactin-dependent conditions.
- Levosulpiride should be used with extreme caution in several patient populations and clinical scenarios due to significant safety concerns.
- It is crucial to assess patients for a history of epilepsy or seizure disorders, as levosulpiride may lower the seizure threshold, potentially precipitating or exacerbating seizures.
- Patients with Parkinson's disease should generally avoid levosulpiride, as its antidopaminergic action can worsen motor symptoms.
- Caution is also warranted in patients with a history of cardiovascular disease, especially those with pre-existing QT interval prolongation, cardiac arrhythmias, or concurrent use of other drugs known to prolong the QT interval, due to the risk of serious ventricular arrhythmias.
- Elderly patients are particularly susceptible to extrapyramidal symptoms, orthostatic hypotension, and sedation, necessitating a lower starting dose and careful monitoring.
- Renal impairment requires significant dosage adjustment to prevent drug accumulation and toxicity.
- The potential for hyperprolactinemia mandates caution in patients with a history of hormone-dependent tumors, such as prolactinoma or breast cancer, as levosulpiride could theoretically promote tumor growth.
- Patients should be advised against driving or operating heavy machinery until they know how the drug affects them, due to the potential for drowsiness or dizziness.
- Abrupt discontinuation, particularly after prolonged use, may lead to withdrawal symptoms or rebound effects, thus gradual tapering is recommended.
- Co-administration with central nervous system depressants or alcohol should be avoided due to additive sedative effects.
How it Works (Mechanism of Action)
Levosulpiride exerts its therapeutic effects primarily through selective antagonism of dopamine D2 receptors. In the central nervous system, this antagonism contributes to its anxiolytic and antidepressant-like properties at lower doses, by potentially modulating dopaminergic neurotransmission in limbic areas. However, at higher doses, it can lead to extrapyramidal symptoms due to D2 blockade in the nigrostriatal pathway. Crucially, in the gastrointestinal tract, levosulpiride's D2 antagonism in the enteric nervous system and chemoreceptor trigger zone (CTZ) confers its prominent prokinetic and antiemetic actions. By blocking presynaptic D2 receptors, it enhances the release of acetylcholine from enteric neurons, thereby increasing lower esophageal sphincter pressure, improving gastric motility, and accelerating gastric emptying. This prokinetic effect is highly beneficial in treating conditions like functional dyspepsia and gastroparesis. Furthermore, antagonism of D2 receptors in the CTZ located in the area postrema of the brainstem inhibits the vomiting reflex, providing its antiemetic efficacy. The selectivity of levosulpiride for D2 receptors, compared to D1, D3, or other neurotransmitter receptors, contributes to its specific therapeutic profile while also being responsible for its endocrine side effects, notably hyperprolactinemia, by inhibiting dopamine's tonic inhibitory control over prolactin secretion from the pituitary gland.